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Abstract
Background: Human embryonic stem cells (hESC) offer a renewable source of a wide range of
cell types for use in research and cell-based therapies to treat disease. Inspection of protein
markers provides important information about the current state of the cells and data for
subsequent manipulations. However, hESC must be routinely analyzed at the genomic level to
guard against deleterious changes during extensive propagation, expansion, and manipulation in
vitro.
Results: We found that short tandem repeat (STR) analysis, human leukocyte antigen (HLA)
typing, single nucleotide polymorphism (SNP) genomic analysis, mitochondrial DNA sequencing,
and gene expression analysis by microarray can be used to fully describe any hESC culture in terms
of its identity, stability, and undifferentiated state.
Conclusion: Here we describe, using molecular biology alone, a comprehensive characterization
of 17 different hESC lines. The use of amplified nucleic acids means that for the first time full
characterization of hESC lines can be performed with little time investment and a minimum of
material. The information thus gained will facilitate comparison of lines and replication of results
between laboratories.
Background
Human embryonic stem cells (hESC) are a potentially
limitless, albeit controversial, source of therapeutic cells
for numerous diseases and injuries. It is likely that differ-
ent hESC lines are best suited to different uses, but at
present, it is rare for any laboratory to work with more
than a few lines. One reason is the expense of these lines;
another is that in the USA hESC are governed by a dual-
track policy. Cell lines derived prior to 9 August 2001
(currently about 20 available lines) can be examined
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using federal funds, and currently much of the available
information on hESC biology has been generated using
these funds and cell lines [1]. However, cell lines derived
after this date are far more numerous, but while it is legal
to work on these lines using non-federal funds, informa-
tion on their properties remains sparse. Government-
funded researchers are reluctant to use these lines given
the difficulties in accounting for federal and non-federal
funds.
The lack of comparative analysis of hESC lines matters,
because the properties and behavior of each line are
uniquely shaped by their histories. It has become clear
that different derivations produce hESC lines that are sim-
ilar overall, but with inherent differences in gene expres-
sion, methylation status, X-chromosome inactivation,
rate of self-renewal, and ability to differentiate [2-4]. More
importantly, the behavior of cells and their phenotypic
state changes as culture conditions and the stress to which
they are subjected is altered, and permanent genomic
changes frequently occur as passage numbers increase [5-
7]. This has led to great difficulty in comparing results
from one laboratory with another and even comparing
results with different passages of the same cell line.
Therefore, thorough and routine characterization of hESC
lines is essential to avoid compromising the validity of
results. The most common characterization method for
hESC is immunocytochemical analysis of a handful of
markers, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-80,
and OCT-3/4 [8]. The next most frequent is reverse tran-
scription PCR, which is used for those group of genes
whose expression is involved in maintenance of the undif-
ferentiated state [9,10]. While these assays certainly give
indications of the undifferentiated state of the cells, they
do not address other issues such as pluripotentiality or the
degree of culture adaptation and genomic instability.
To facilitate comparisons among lines, the hESC research
community has begun to develop a number of tools.
Work is proceeding toward conditions that support the
propagation of all lines [11], sets of markers that truly
define the undifferentiated and unadapted state of the
cells [7,12-14], and markers predictive of the differentia-
tion capacity of the cells [15]. The work presented here is
part of efforts to create a database of the properties of each
line and to identify a reference standard for comparisons
between laboratories. To this end, we have assembled a set
of molecular tests for hESC lines that assess identity, sta-
bility of the nuclear and mitochondrial genomes, histo-
compatibility profile, and the undifferentiated state of the
cells. Some of these assays have been previously per-
formed on individual lines, but to our knowledge, no sin-
gle group has used all of these tests on any single line, and
few comparisons between lines have been made publicly
available.
In this paper, we describe the analysis of multiple lines
and show that this entire set of tests can be performed
with a minimal sample size and over a short time period,
and that these tests allow comparison of datasets across
cell lines (a critical requirement to permit rapid progress
in the field). We suggest that an internet database of hESC
characterization data and standard reference materials
will permit the research community to readily compare
cell lines without the necessity of growing all lines in their
own laboratory or tracking pre- and post-9 August cell
lines.
Results
The 17 cell lines analyzed are listed in Table 1. The lines
were grown on feeders, or feeder-free on fibronectin,
using bovine, human, or artificial serum according to the
providers' protocols (see Methods).
Measures of identity
The results of short tandem repeat (STR) analysis of these
lines are shown in Figure 1. The eight STR markers plus
amelogenin used here are capable of identifying individ-
ual human genomes with a discrimination of 1 in hun-
dreds of millions [16]. Each of the early passage lines
studied here was shown to be genetically distinct from the
others. Each late passage line or karyotypically abnormal
subline (BG01V, SA02) is identical to the early passage
line, showing no evidence of overgrowth by contaminat-
ing cells. Only two instances of possibly heterogeneous
cultures are observed. Cultures of the I6 line were grown
in two separate laboratories, and one of these cultures
shows a reproducible abnormality in the chromosome 13
microsatellite marker D13S317. One culture at passage 44
shows a third allele (with 12 repeats) for this marker; the
low intensity of the signal suggests either an abnormal
subpopulation or lessened PCR efficiency. The second cul-
ture, grown independently to passage 47, shows two nor-
mal alleles at all loci. The second abnormal observation
was also found at the D13S317 locus in the line SA02.
This line shows three distinct alleles at passage 29, consist-
ent with trisomy 13 as shown in the karyotype [17]. In
contrast, the karyotypically normal subline SA02.5, which
was subcloned from SA02, carries only two alleles on
chromosome 13. The lines H7 and H9 show no changes
visible by STR between lower and higher passage num-
bers.
The histocompatibility profile of each line was deter-
mined by sequence-specific oligonucleotide probes, and
is summarized in Table 2. Each line has a unique histo-
compatibility profile, while the two sublines SA02.5 and
BG01V are identical to their parental lines. Only theBMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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NTERA-2 embryonal carcinoma line shows an atypical
histocompatibility profile, being homozygous at all tested
loci.
Measures of stability
Finer resolution analysis of genomic stability is afforded
by single nucleotide polymorphism (SNP) assays. In this
analysis, over 100,000 SNPs were assayed by microarray.
The average SNP spacing in the genome is 26 kb.
Figure 2 shows examples of hESC lines compared at low
and high passage (H7 and H9), and comparison of karyo-
typically normal lines (BG01 and SA02.5) with karyotyp-
ically abnormal derivative lines (BG01V and SA02). SNP
analysis can detect loss of heterozygosity (LOH) at any
locus where two alleles were originally present, and is fre-
quently used in analysis of tumors for discovery of poten-
tial oncogenes and anti-oncogenes [18]. In addition,
comparison of intensity signals can be used to calculate
copy number at all loci [19,20], and this has been recently
used to detect genomic amplifications and deletions in
hESC [6].
Comparison of the signal intensity and separation angle
of all SNPs shows distinct discontinuities over certain
chromosomes (Figure 2). This is the same approach used
with Affymetrix SNP arrays to determine copy number
[21]; however, reference BeadArray data from known dip-
loid loci is required to translate intensities into copy
number. Nevertheless, local changes in the allele intensity
ratio (theta) are seen in chromosomes 12, 17, and a por-
tion of chromosome X of BG01V, chromosome 13 of
SA02, and within the q arm of chromosome 1 in H9. All
of these areas have previously been shown to be dupli-
cated in these cell lines [6]. No other significant disconti-
nuities were found for any other chromosome of any line.
Sequencing of the entire mitochondrial genome
(16,544bp) was performed using an oligonucleotide
sequencing microarray (Affymetrix MitoChip v2.0), as
previously described [6]. Briefly, 'early' and 'late' passages
of nine paired hESC lines (BG01, BG02, BG03, HES2,
HES3, SA01, SA02, H7, and H9) were sequenced for alter-
ations in mtDNA in the course of in vitro passage. The
results of this study have been published elsewhere [6],
and six heteroplasmic sequence alterations occurring in
two of nine (22%) later passage hESC lines were identi-
fied and confirmed by conventional dideoxy sequencing.
The raw MitoChip data on the nine hESC lines is available
on request (from AM).
Measures of pluripotency
Gene-expression analysis was performed by BeadArray
(Illumina) to assay the transcriptome of each line. RNA
expression profiles of several lines were directly compared
with RNA from a pool of three undifferentiated lines pre-
viously used to compare expression by EST enumeration
and MPSS [15,22] (Figure 3). The normal lines tested (H9,
I6, BG01, BG02, and BG03) show an average correlation
coefficient (r2) of 0.93 for genes detected with high confi-
dence (>0.99). Karyotypically abnormal ES and EC lines
(BG01V and NTERA-2) produce r2 values of 0.92 and
0.88, respectively. This suggests that overall gene expres-
sion is more sensitive to the difference between normal
and culture-adapted lines than is the use of immunocyto-
chemical markers.
Table 1: Cell lines analyzed
Embryonic stem cell line NIH Registry name Passage no Reference STR HLA SNP mtDNA Gene exp.
BG01 BG01 P43 Brimble et al, 2004 + + + + +
BG01V BG01V P25 Zeng et al, 2004 + + + + +
BG02 BG02 P13, P14 Brimble et al, 2004 + + + +
BG03 BG03 P14 Brimble et al, 2004 + + + +
I3 TE03 P38 Amit and Itskovitz-Eldor, 2002 +
I6 TE06 P44, P47 Amit and Itskovitz-Eldor 2002 + + +
I4 TE04 P29 Amit and Itskovitz-Eldor 2002 + +
H1 WA01 P80 Thomson et al, 1998 + + +
H7 WA07 P41, P63 Thomson et al, 1998 + + + +
H9 WA09 P33, P78 Thomson et al, 1998 + + + + +
hES2 ES02 P55, P146, P147 Reubinoff et al, 2000 + + +
hES3 ES03 P59, P92, P93 Reubinoff et al, 2000 + + +
SA01 SA01 P14, P25, P32, P60 Heins et al, 2004 + + +
SA02 SA02 P29 Heins et al, 2004 + + + +
SA02.5 SA02.5 P155+49 + + + +
Relicell™ hES1 Not registered P30 Mandal et al, 2006 + +
HUES-7 Not registered P14 Cowan et al, 2004 + +
+ indicates assays performed and reported in this publication.
Exp., expression.BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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Not all genes contribute equally to the pluripotency of
hESC, of course. Recent work comparing the transcrip-
tomes of multiple hESC lines has identified core sets of
105 ES-specific genes [12] and 194 genes specifically
upregulated in differentiating embryoid bodies [14],
which have been used to create focused arrays for hESC
testing. Of the ES-specific genes, 96 could be identified
and detected at high confidence in our pooled hESC lines
(Table 4). Nearly all of these were detected at similar lev-
els in all of the individual hESC lines tested (H9, BG01,
BG01V, BG02, BG03 and I6) and in the EC line NTERA-2.
Every line but BG01 under- or over-expressed by 2.5-fold
at least one ES marker, especially I6, which underex-
pressed 11 genes including TDGF-1, REX-1, and UTF-1.
Few ES-specific genes were overexpressed, except for the
variant line BG01V, which overexpressed four genes,
including  ABCG2, and NTERA-2, which overexpressed
two genes, including the germ cell tumor marker GDF3.
Of the 192 differentiation-specific genes, 168 could be
detected at a significant level in the pooled hESC lines.
Approximately 89–96% of these were also detected in any
individual line, except for BG01V, in which 134 genes
were significantly expressed. This agrees with previous
findings of low-level expression of diverse differentiation
markers in undifferentiated hESC [23]. NTERA-2 and I6
underexpressed the greatest number of these markers,
while H9 and NTERA-2 also overexpressed six EB-specific
genes each. In H9, three of these were collagen genes, sug-
gesting the presence of human fibroblasts possibly differ-
entiated from the hESC grown under feeder-free
conditions.
Discussion
The technical demands of culturing human embryonic
stem cells are already well known in the field. It is now
becoming clearer that frequent characterization of the
cells in culture must be added to the burden. The present
data confirm the general finding that hESC lines in culture
accumulate genomic, epigenetic, and mitochondrial
changes within as few as 22 passages [6]. As a result, labo-
ratories attempting to expand hESC lines must subject
them to frequent characterization tests sensitive to aberra-
tions below the resolution of G-banded karyotypes. The
number and frequency of required tests also increases the
value of rapid and convenient test methods, such as the
many array-based molecular tests currently on the market
or in development. This manuscript presents a molecular
characterization scheme for hESC lines that helps to
define the state of the cells. The tests include measures of
identity, stability, and self-renewal, and the undifferenti-
ated state of the cells. In addition, we have provided data
on potential reference standards for hESC research. We
show by examples that each of these tests offers important
insights into the state of the hESC line and that the com-
STR analysis for identification Figure 1
STR analysis for identification. STR profile of human 
embryonic stem cell lines. Loci analyzed by the PowerPlex 
1.2 system (Promega) comprise D5S818, D13S317, D7S820, 
D16S539, vWA, TH01, TP0X, CSF1P0, and the sex-chromo-
some marker amelogenin. Data were collected on an ABI 
310 genetic analyzer, and analyzed using Genescan 3.1 and 
Genotyper 2.0 software (all Applied Biosystems).BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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bination of these tests provides a unique characterization
profile of a given cell line that is sensitive to the deleteri-
ous changes that can occur in culture.
This initiative, led by the American Type Culture Collec-
tion (ATCC) and supported by most of the providers of
hESC lines, represents a complementary effort that uses
cell lines approved by the National Institutes of Health to
develop a basis for comparison across different laborato-
ries. Equally important, by providing data in the same for-
mat on a new post-9 August line, it facilitates the direct
comparison of lines eligible and ineligible for federal
funding to determine which cell line is best suited to the
individual researcher's needs. Such a comparison has not
to our knowledge been previously performed, as it is
largely impossible for most researchers in the USA.
Our estimate of testing costs for this characterization
scheme is that these can be completed for a single line for
approximately $2500. The identity, stability, and undif-
ferentiated state of lines can be assessed with less than 5
μg of genomic DNA and 100 ng of total RNA. This can be
obtained from 2–3 million cells, comparable with the
amount required to run a single karyotype analysis using
Giemsa-banded metaphase spreads. We further note that
it will not be necessary for every researcher to repeatedly
perform every one of these tests. We have identified com-
mercial service providers both within and outside the
USA, which can perform these analyses, and ATCC and
other banks have offered to similarly characterize the lines
they maintain.
The characterization scheme is composed of tests chosen
on the basis of comprehensiveness, wide availability, and
cost efficiency. For example, STR analysis as a measure of
identity is a simple PCR-based analysis that is available in
a kit from multiple providers, and can be readily run in
any laboratory. One advantage of this assay is that it also
readily distinguishes male and female samples, and in
theory can be used to examine relatedness between sam-
ples and the larger database sets that have been generated
for other purposes. ATCC is developing a comprehensive
database of DNA profiles of hESC and other human cell
lines based on STR loci [24]. This test allows for discrimi-
nation of at least 1 in 100 million individuals [16].
HLA typing of hESC lines is essential, both for future use
in transplantation and for the immediate goal of estimat-
ing how many hESC lines are required to meet the needs
of all potential patients [25]. HLA typing at the allelic level
included HLA-A, HLA-B, HLA-C, HLA-DRB, and HLA-
DQB loci.
SNP arrays are commonly used for mapping new markers
of genetic disease and for detecting LOH in cancer.
Recently, algorithms have been developed that allow oli-
gonucleotide SNP arrays to measure chromosomal copy
number at high resolution [19,20]. This expands the util-
Table 2: STR results
Locus ID
Designation D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
BG01 10, 12 11, 12 10, 11 9, 11 16, 17 7, 9.3 X, Y 8 10
BG01V 10, 12 11, 12 10, 11 9, 11 16, 17 7, 9.3 X, Y 8 10
BG02 11, 12 11 12, 14 12 18, 19 8, 9 X, Y 11 8, 10
BG03 13 8, 12 11 11, 13 16 6, 7 X 8 12
I3 11, 12 12, 14 10, 11 11, 12 16, 17 7, 9 X 8 11, 12
I6-P44 12 8, 11, 12 8, 10 9, 13 16, 17 8, 9.3 X, Y 10, 11 10, 11
I6-P47 12 8, 11 8, 10 9, 13 16, 17 8, 9.3 X, Y 10, 11 10, 11
I4 11, 12 12, 14 12, 13 11, 12 16, 18 7, 9 X 8 12
H1 9, 11 8, 11 8, 12 9, 13 15, 17 9.3 X, Y 8, 11 12, 13
H7-P41 11, 13 11, 12 10, 11 12, 13 14, 15 6 X 8, 11 12
H7-P63 11, 13 11, 12 10, 11 12, 13 14, 15 6 X 8, 11 12
H9-P33 11, 12 9 9, 11 12, 13 17 9.3 X 10, 11 11
H9-P78 11, 12 9 9, 11 12, 13 17 9.3 X 10, 11 11
hES2 11 8, 11 9, 11 9, 12 18, 20 7, 9 X 8, 12 11
hES3 10, 12 9, 12 11, 12 9 17, 18 7, 9 X 8 12
SA01 12, 13 11, 12 8, 10 12, 13 16, 18 9.3 X, Y 8, 9 10, 13
SA02 12 9, 11, 14 10, 12 12, 14 14, 16 9, 9.3 X 8, 9 11, 12
SA02.5 12 9, 11 10, 12 12, 14 14, 16 9, 9.3 X 8, 9 11, 12
Relicell™ hES1 11, 12 10, 11 9, 12 11, 12 18 9 X 10, 11 10, 11
HUES-7 11, 13 11, 12 8, 11 11, 12 16, 18 6, 9.3 X, Y 8 12
NTERA-2 9, 12 13 10, 12 11,12,13 18, 19 9.3 X, Y 8 10, 12BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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Copy number analysis by SNP array Figure 2
Copy number analysis by SNP array. DNA from hESC was amplified by PCR and hybridized to Sentrix BeadArrays. Paired 
lines (low versus high passage or karyotypic normal versus variant sublines) were compared at 101,000 loci. The 25-SNP mov-
ing average of the difference in allele intensity ratios is shown above the axis (red). (A) hESC line H7 compared at 41 and 63 
passages. (B) hESC line H9 compared at 33 and 78 passages. (C) hESC line SA02.5 compared with the karyotypic variant SA02 
(+13). (D) hESC line BG01 compared with the karyotypic variant subline BG01V (+12, +17, +X).BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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Gene expression analysis by BeadArray Figure 3
Gene expression analysis by BeadArray. RNA samples from six human ES cell lines and one human EC line were analyzed 
by Illumina BeadArray, and scatterplots were made by comparing individual lines with pooled ES cell samples. Genes that were 
detected at >0.99 confidence from the array were labeled blue, and genes falling outside of the red lines were detected at >2.5-
fold difference. Total gene numbers and values of the correlation coefficient (r2) of all comparisons were summarized in the 
table.B
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Table 3: HLA profiles
Locus HLA-A HLA-B HLA-C DRB1 DRB3 DRB5 DQB1
BG01 Allele code 02XX, 03XX 35XX, 49XX 04XX, 07XX 03VEW, 04DAZ 01ANEX 02XX, 03XX
Serological equivalent A2, A3 B35, B49 Cw4, Cw7 DR3, DR4 DR52 DQ2, DQ3
BG01V Allele code 02XX, 03XX 35XX, 49XX 04XX, 07XX 03VEW, 04DAZ 01ANEX 02XX, 03XX
Serological equivalent A2, A3 B35, B49 Cw4, Cw7 DR3, DR4 DR52 DQ2, DQ3
BG02 Allele code 24AZMA, 68AZMC 3511, 35MWA 03XX, 04XX 15ANVF, 1602 01KBE 03NX, 0601
Serological equivalent A24, A68 B35, B35 Cw3, Cw4 DR15, DR16 DR51 DQ3, DQ6
BG03 Allele code 24AZMA, 68AZMC 44AZZX, 44AZNT 05XX 04ANUK, 04JRG 03XX
Serological equivalent A24, A68 B44, B44 Cw5 DR4, DR4 DQ3
I6 Allele code 01ADJA, 26TJW 38AF, 44AZKJ 04XX, 12XX 04BK, 07YRE 02XX, 03XX
Serological equivalent A1, A26 B38, B44 Cw4, none DR4, DR7 DQ2, DQ3
I4 Allele code 03ANPZ, 24BCKM 3502, 38AF 04XX, 12XX 13ANYX, 13AMGH 01ANUB 06XX
Serological equivalent A3, A24 B35, B38 Cw4, none DR13, DR13 DR52 DQ6
H1 Allele code 02BBNK, 03ANPZ 08ARGR, 35ASKY 04XX, 07XX 01AMFN, 03VEW 01ANEX 02XX, 05XX
Serological equivalent A2, A3 B8, B35 Cw4, Cw7 DR1, DR3 DR52 DQ2, DQ5
H7 Allele code 02BABR, 25AC 18AZYW, 35AZZE 04XX, 12XX 07SAF, 11BBBW 02ARZT 02XX, 03XX
Serological equivalent A2, A25 B18, B35 Cw4, none DR7, DR11 DR52 DQ2, DQ3
H9 Allele code 02AZKW, 03ARDP 35JXF, 44AZZW 04XX, 07XX 15BCFX, 1601 01AUMM 05XX, 06XX
Serological equivalent A2, A3 B35, B44 Cw4, Cw7 D15, D16 DR51 DQ5, DQ6
hES-2 Allele code 0203, 02BBFJ 46AB, 48AC 01XX, 08XX 04ASVM,15AUAM 01REZ 04XX, 06XX
Serological equivalent A2, A2 B46, B48 Cw1, Cw8 DR4, DR15 DR51 DQ4, DQ6
hES-3 Allele code 11ZPJ, 33DWH 40ADGG, 55GEJ 01XX, 07XX 12ARRT, 12ATDH 01AUPH 06XX
Serological equivalent A11, A33 B60, B55 Cw1, Cw7 DR12, DR12 DR52 DQ6
SA01 Allele code 01ADVC, 02AZUK 07AZMH, 35RYF 04XX, 07XX 13ASTS, 15UVF 02UPA 01REZ 06XX
Serological equivalent A1, A2 B7, B35 Cw4, Cw7 DR13, DR15 DR52 DR51 DQ6
SA02 Allele code 01ADVC, 23ARDZ 07AZHW, 51AZJX 07XX, 15XX 14ASYK, 14AMRN 02AJHF 05XX
Serological equivalent A1, A23 B7, B51 Cw7, none DR14, DR14 DR52 DQ5
SA02.5 Allele code 01ADVC, 23ARDZ 07AZHW, 51AZJX 07XX, 15XX 14ASYK, 14AMRN 02AJHF 05XX
Serological equivalent A1, A23 B7, B51 Cw7, none DR14, DR14 DR52 DQ5
Relicell hES1 Allele code 01WUS, 02BCKD 5601, 35ASKY 01XX, 04XX 01AMFN, 01CRM 05XX
Serological equivalent A1, A2 B56, B35 Cw1, Cw4 DR1, DR1 DQ5
HUES7 Allele code 02BBNK, 03ANPZ 35CU, 51ASMM 04XX, 14XX 04YEP, 15AK 01XTV 03XX, 06XX
Serological equivalent A2, A3 B35, B51 Cw4, none DR4, DR15 DR51 DQ3, DQ6
NTERA-2 Allele code 01ADJA 08AZMJ 07XX 03ASDU 01ASFC 02XX
Serological equivalent A1 B8 Cw7 DR3 DR52 DQ2BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
Page 9 of 13
(page number not for citation purposes)
ity of SNPs to detect non-reciprocal translocations, aneu-
ploidy, and partial amplifications or deletions of
chromosomes. Maitra et al have used this method to show
that hESC in culture can acquire amplifications or dele-
tions of small chromosomal regions [6]. The SNP array
method is of great value in characterizing hESC lines, as it
improves the resolution for detecting genetic alterations.
Conventional Giemsa-stained karyotypes or spectral kary-
otypes have a resolution of about 1–5 Mb. Comparative
genomic hybridization (CGH) of metaphase spreads has
a resolution of approximately 20 Mb, and array-based
CGH with genomic or cDNA clones has improved this to
<1 Mb. Bacterial artificial chromosome clone arrays have
now improved the resolution to <100 kb. In contrast, cur-
rently available arrays of 100,000 SNPs have a potential
resolution of about 25 kb. With over 2 million SNPs
already mapped in the human genome, increased density
arrays could drop this even further.
Like SNP genotyping, sequencing of the mitochondrial
DNA offers the dual benefits of measuring identity (across
16,544 bases comprising a large number of polymorphic
haplotypes) as well as stability over passages. Mitochon-
drial genes accumulate mutations in the somatic cells of
aging animals. Mice in which mtDNA damage is acceler-
ated show numerous symptoms of premature aging [26].
The connections between tissue stem cells and aging are
still controversial, but it has been demonstrated that
changes in mitochondrial properties correlate with
reduced competence of adult stem cells [27]. Thus,
although mtDNA mutations are quite common in
somatic cells, the functional consequences may be greater
in stem cells. Array-based sequencing of mtDNA is cost
effective, and the reduced number of reactions needed in
long-range PCR reactions and the automated analysis of
genotype data using the RA Tools software (see Methods)
significantly decreases analysis time.
Measures of identity and stability are generally of less con-
cern to researchers growing hESCs than are the potency
and undifferentiated state of the cells. These qualities are
generally assessed by antibody staining for protein
biomarkers. However, with the ability to rapidly assess
expression of all human genes, it is possible to measure
the expression of undifferentiated markers and any con-
ceivable differentiation marker in a single step. The gene-
expression profile of pluripotent hESCs has not been
completely defined, but much work has been carried out
toward defining common sets in undifferentiated and dif-
ferentiating hESCs [12-14]. The use of this microarray
method to distinguish undifferentiated and differentiated
hESC cultures has been demonstrated [27]. This gives the
possibility of assigning a quality score to any hESC cul-
ture, which will be of value in improving culture methods.
The main drawback of these molecular methods is that
the cells are assayed as an amalgam, so the ability to detect
differentiated cells or aberrant subpopulations must be
demonstrated. For example, we have estimated that at
least 20% of the population must carry a genetic abnor-
mality before it can be detected by a SNP array (data not
shown). Currently, this method is often used to screen for
LOH in cancer. Normal cells within the tumor severely
degrade the sensitivity of LOH detection when as few as
10% are present, but copy-number detection is less sensi-
tive to mixed populations [28]. Similarly, the presence of
low levels of differentiated cells is likely to escape notice
when surveying global gene expression. The data pre-
sented here shows the overexpression of collagen genes in
a sample of hESC cultured in feeder-free conditions,
which suggests that the microarray method can detect dif-
ferentiating subpopulations, but there is no way to retro-
spectively determine the level of differentiation.
Owing to the demands of culturing hESCs, it is rare that
any one laboratory will bring together numerous lines to
compare them under identical conditions. Thus, compar-
isons must be facilitated between laboratories by the
promulgation of standard reference materials. The present
work has thus compared multiple hESC lines to several
potential reference materials, each having advantages in
different areas of hESC research.
The greatest need for standards is in the area of gene-
expression studies, as whole genome arrays are still expen-
sive enough to discourage broad comparisons in any one
Table 4: Expression of hESC- and EB- specific genes
hESC pool H9 NTERA-2 BG01 BG02 BG01V BG03 I6
Undifferentiated hESC genes (n =  1 0 4 ) 9 6 9 5 9 4 9 29 48 8 9 49 2
Underexpressed <0.4 × - 2 4 0 1 1 2 11
Overexpressed >2.5 × - 0 2 0 1 4 1 0
Embryoid body genes (n = 196) 168 162 158 154 152 134 156 149
Underexpressed <0.4 × - 2 10 6 6 5 6 11
Overexpressed >2.5 × - 6 6 0 0 0 3 1BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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laboratory, and the results are not easily compared
between laboratories. For gene expression studies, we
have created a pool of RNA from three independent hESC
lines. This pool shows great concordance of expression
with individual normal hESC lines, as the correlation
coefficients (r2) with normal lines average 0.87, or 0.93
for genes expressed at high confidence levels. Even if the
line H9, one of the lines in the pooled samples, is
excluded, the r2 of highly confident expression for normal
ES lines averages 0.93. Thus, the pooled sample shows
high colinearity with hESC lines of diverse origin. As the
RNA pool can be captured in the form of a cDNA library
relatively inexpensively, it can easily be widely dissemi-
nated.
Alternatively, we have also provided data on embryonal
carcinoma and karyotypically abnormal hESC lines,
which are potential reference materials. As these lines are
freely available, relatively inexpensive, and not subject to
licensing and patent permissions, it is feasible to run these
lines as internal/normalization controls. Internal refer-
ence standards also allow normalization of data to posted
datasets available worldwide. NTERA-2 is an embryonal
carcinoma line that expresses the same early embryo anti-
gens now used to identify undifferentiated hESC. In glo-
bal gene-expression studies, such as the data presented
here, NTERA-2 closely mimics hESC lines, showing an
average r2 with the hESC pool of 0.84 for all genes and
0.88 for genes at high confidence. Reference material in
the form of RNA or cDNA could easily be produced in
large lots from this cell line, for distribution around the
world. The NTERA-2 line also has advantages for anti-
body-based comparisons, as the line is well adapted to
culture and grows quickly without feeder layers, attach-
ment matrices, or the addition of any specialized growth
factors other than serum. If the phenotype of NTERA-2
were compared between laboratories, this last would
probably be the major source of variation. Thus, an effort
could be made to introduce standardized serum-free con-
ditions for the growth of NTERA-2 and validate the repro-
ducibility of its gene expression across laboratories in
order to create an unlimited source of reference material
for hESC.
While the undifferentiated phenotype of NTERA-2 is quite
similar to that of hESCs, its behavior in differentiation
paradigms is quite different. It shows little spontaneous
differentiation in culture without induction by retinoic
acid or other chemicals [29,30]. Therefore, it may be more
advantageous to have a reference material that is grown in
conditions identical to normal hESC and shows a similar
capacity for differentiation in vitro [31] and in vivo [32].
The aneuploid line BG01V has these characteristics. Com-
pared with NTERA-2, the overall gene-expression profile
of BG01V is more similar to undifferentiated hESC lines
(r2 = 0.87 for all genes, 0.92 for genes at high confidence).
The gene expression of differentiating cultures is being
examined, but is much more likely to mimic differentiat-
ing hESCs than NTERA-2 would. For whole-cell studies of
differentiation, BG01V is available at low cost. The growth
conditions for BG01V, as for hESC in general, have not yet
been standardized to ensure reproducible results across
laboratories.
Conclusion
In summary, we have found that the molecular character-
ization of hESC can be performed with minimal material,
time, and expense. The series of tests presented here pro-
vides a method for frequent monitoring of many of the
properties thought to be involved in stem-cell pluripo-
tency. We believe that such characterization provides a
useful set of results that will aid the cooperative interna-
tional stem-cell effort, and will allow progress to be more
rapid than in the past. We also hope that as cooperative
standards become more widely accepted, commercial
organizations will see fit to offer these as tools or kits to
make the work of individual researchers easier.
Methods
Establishment and culture of human embryonic stem cell 
lines
All hESC lines were grown under similar conditions, with
variations dictated by the providers' protocols. The stand-
ard culture medium was Dulbecco minimal essential
medium (DMEM)/F12-Glutamax, 20% KnockOut Serum
Replacement (KSR), 2 mM nonessential amino acids, 100
μM beta-mercaptoethanol (all from Invitrogen, Carlsbad,
CA, USA), 50 μg/ml penicillin/streptomycin, and 4 ng/ml
human recombinant basic fibroblast growth factor (FGF2;
PeproTech Inc., Rocky Hill, NJ, USA) Feeder-free cultures
were supplemented with FGF2 at 20 ng/ml.
TE06 (I6): Cells were cultured for 30 passages on mouse
embryonic fibroblast (MEF) layers in KnockOut DMEM
supplemented as above, except for the use of 5% fetal calf
serum and 15% KSR (Invitrogen).
BG01, BG02, BG03 and BG01V: Cells were maintained
under feeder-free condition on fibronectin-coated plates
in medium that had been conditioned by mouse-embryo
fibroblasts for 24 hours.
WA09 (H9): Human ES cell line H9 (WiCell, Madison,
WI, USA) were cultured on feeder layers derived from
mitotically inactivated WA09-derived mesenchyme or
under feeder-free conditions on Matrigel- or human lam-
inin-coated plates for at least 10 passages.
HUES-7: cells were maintained on a feeder layer of mito-
mycin C-treated CF-1 mouse embryonic fibroblasts (MEF)BMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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(ATCC, SCRC-1040.2). Growth medium was ES-DMEM
(ATCC) supplemented with plasmanate (10%) (Bayer),
KSR (10%; Invitrogen), L-alanyl-L-glutamine (2.0 mM;
ATCC), non-essential amino acids (1X; ATCC), β-mercap-
toethanol (0.055 mM; Invitrogen), penicillin (100 IU/
mL) and streptomycin (100 μg/mL) (both ATCC), and
FGF2 (12 ng/mL; R&D Systems, Inc.).
Cells were passaged every 4–5 days using collagenase IV
(200 U/mL; Invitrogen) except HUES-7, which were pas-
saged using 0.05% trypsin/EDTA (Invitrogen).
STR typing
Frozen cell pellets were resuspended in 1× phosphate-
buffered saline (PBS). A 20-mL aliquot was spotted onto
a labeled FTA® card (Whatman) and allowed to dry. The
FTA card lyses the cells on contact and binds the DNA to
the paper surface. Prior to PCR, a portion of the dried spot
was removed with a Harris punch, washed three times
with purification reagent (Whatman), washed once with
Tris-EDTA (TE) buffer (pH 8.0), and allowed to dry. STR
analysis was conducted using the multiplex-PCR-based
PowerPlex 1.2 kit (Promega Corporation). Loci analyzed
include D5S818, D13S317, D7S820, D16S539, vWA,
TH01, amelogenin, TP0X and CSF1P0. Electropherogram
data were collected on an ABI 310 genetic analyzer
(Applied Biosystems). Data was analyzed using Genescan
3.1 and Genotyper 2.0 software (Applied Biosystems).
The resulting profile was imported into an in-house data-
base and screened against all other baseline profiles of all
samples tested by the ATCC. STR analysis of the NTERA-2
cell line was performed similarly using isolated genomic
DNAs.
HLA typing
Genomic DNA was isolated from cells using the GenE-
lute™ mammalian genomic DNA miniprep kit (Sigma-
Aldrich, Inc.). HLA DNA typing was performed by utiliz-
ing hybridization of PCR-amplified DNA with sequence-
specific oligonucleotide probes (SSOP) (Tepnel Lifecodes
Corporation). The target DNA is amplified by PCR and
then allowed to denature and rehybridize to complemen-
tary DNA probes conjugated to fluorescently coded micro-
spheres. A flow analyzer identifies the fluorescent
intensity on each microsphere, and the determined HLA
type is based on the reaction pattern compared with pat-
terns associated with public HLA gene sequences. Assays
were performed to determine the HLA-A, HLA-B, HLA-C,
HLA-DRB, and HLA-DQB loci.
SNP analysis
Genomic DNA isolated as above was amplified following
the Infinium™ whole genome genotyping assay [32] and
hybridized to a prototype Sentrix BeadArray (Illumina
Inc., San Diego, CA, USA). Allele calls were made by Gen-
Call software (Illumina Inc.).
Gene expression analysis
Feeder-free cultures were prepared for gene expression
analysis by manually harvesting individual colonies with
uniform typical undifferentiated ES cell morphology.
Feeder-containing cultures were harvested by scraping
both ES and feeder cells. WA01 (H1), WA07 (H2), and
WA09 (H9) cells were cultured under feeder-free condi-
tions, and pooled prior to RNA isolation.
RNA was isolated from cultured cells using the Qiagen
RNEasy kit (Qiagen, Inc, Valencia, CA, USA). Sample
amplification was performed using 100 ng of total RNA as
input material by the method of Van Gelder et al [33]
using the Illumina® RNA amplification kit (Ambion Inc.,
Austin, TX, USA) following the manufacturer's instruc-
tions. Labeling was achieved by incorporating biotin-16-
UTP (Perkin-Elmer Life and Analytical Sciences, Boston,
MA, USA) present at a ratio of 1:1 with unlabeled UTP.
Labeled, amplified material (700 ng per array) was
hybridized to a pilot version of the Illumina Ref-8 Bead-
Chip according to the manufacturer's instructions (Illu-
mina Inc.). Arrays were washed then stained with
Amersham FluoroLink streptavidin-Cy3 (GE Healthcare
Bio-Sciences, Little Chalfont, Buckinghamshire, UK) fol-
lowing the BeadChip manual. Arrays were scanned with
an Illumina BeadArray Reader confocal scanner according
to the manufacturer's instructions. Array data processing
and analysis was performed using Illumina BeadStudio
software.
Mitochondrial DNA sequencing
Genomic DNA was extracted from paired hESC lines, and
PCR amplified in three long-range PCR reactions as previ-
ously described [34]. Amplified DNA was pooled, frag-
mented. and labeled as described in the Affymetrix
CustomSeq™ resequencing protocol. MitoChips were
hybridized overnight, washed on the Affymetrix fluidics
station using the pre-programmed CustomSeq™ rese-
quencing wash protocols, and scanned. Data analysis was
performed using RA Tools, a modified version of the pre-
viously described adaptive background genotype-calling
scheme (ABACUS) [35]; the open-source software is avail-
able from the Drosophila  Population Genomics Project
[36]. Briefly, RA Tools uses an objective statistical frame-
work to assign each genotype call a 'quality score', which
is the difference between the log10 likelihood of the best-
fitting and the second-best-fitting statistical model for
assigning a genotype at any position on the sequencing
array. The total quality-score threshold (totThresh) is the
quality score that a given base has to exceed in order to be
called. Increasing this value requires increased support for
base calls, and consequently, fewer bases are called. BasesBMC Biology 2006, 4:28 http://www.biomedcentral.com/1741-7007/4/28
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that fail to reach this threshold are called 'N.' The opti-
mum total threshold quality score is determined empiri-
cally to be 12, which yields the highest base-call rate with
the lowest discrepancy between genotypes for replicate
samples. Confirmation of array-based sequencing was
performed with a dye-terminator platform using the ABI
Big Dye cycle sequencing kit (Applied Biosystems).
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